Brown Advisory Inc. Acquires Shares of 227,412 ICU Medical, Inc. $ICUI

Brown Advisory Inc. acquired a new stake in ICU Medical, Inc. (NASDAQ:ICUI) during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 227,412 shares of the medical instruments supplier’s stock, valued at approximately $32,445,000.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Millennium Management LLC lifted its position in shares of ICU Medical by 173.4% during the 3rd quarter. Millennium Management LLC now owns 1,089,017 shares of the medical instruments supplier’s stock valued at $130,638,000 after acquiring an additional 690,694 shares during the period. Norges Bank bought a new stake in shares of ICU Medical during the 4th quarter worth $58,083,000. Thrivent Financial for Lutherans lifted its position in shares of ICU Medical by 1,604.0% during the 4th quarter. Thrivent Financial for Lutherans now owns 303,457 shares of the medical instruments supplier’s stock worth $43,294,000 after buying an additional 285,648 shares during the last quarter. UBS Group AG lifted its position in shares of ICU Medical by 239.8% during the 3rd quarter. UBS Group AG now owns 386,555 shares of the medical instruments supplier’s stock worth $46,371,000 after buying an additional 272,782 shares during the last quarter. Finally, Ameriprise Financial Inc. lifted its position in shares of ICU Medical by 34.0% during the 3rd quarter. Ameriprise Financial Inc. now owns 803,542 shares of the medical instruments supplier’s stock worth $96,393,000 after buying an additional 203,746 shares during the last quarter. 96.10% of the stock is owned by institutional investors and hedge funds.

ICU Medical Price Performance

ICU Medical stock opened at $143.72 on Tuesday. The company has a current ratio of 2.34, a quick ratio of 1.17 and a debt-to-equity ratio of 0.60. The company has a market capitalization of $3.59 billion, a PE ratio of 77.69, a P/E/G ratio of 1.99 and a beta of 0.77. ICU Medical, Inc. has a 12 month low of $107.00 and a 12 month high of $160.29. The stock has a 50-day moving average price of $128.53 and a two-hundred day moving average price of $138.66.

ICU Medical (NASDAQ:ICUI) last posted its earnings results on Thursday, May 7th. The medical instruments supplier reported $1.97 EPS for the quarter, beating the consensus estimate of $1.78 by $0.19. The firm had revenue of $525.77 million during the quarter, compared to the consensus estimate of $520.65 million. ICU Medical had a return on equity of 7.50% and a net margin of 2.15%.The business’s quarterly revenue was down 12.3% on a year-over-year basis. During the same period last year, the company earned $1.72 earnings per share. ICU Medical has set its FY 2026 guidance at 7.750-8.450 EPS. Analysts expect that ICU Medical, Inc. will post 6.5 EPS for the current year.

Wall Street Analysts Forecast Growth

Several analysts recently weighed in on the company. Needham & Company LLC upgraded ICU Medical from a “hold” rating to a “buy” rating and set a $165.00 price objective for the company in a research report on Wednesday, May 27th. Sanford C. Bernstein downgraded ICU Medical to a “market perform” rating in a research report on Monday. Jefferies Financial Group upgraded ICU Medical to a “strong-buy” rating in a research report on Thursday, May 7th. Wall Street Zen upgraded ICU Medical from a “hold” rating to a “buy” rating in a research report on Saturday, May 9th. Finally, Weiss Ratings upgraded ICU Medical from a “sell (d)” rating to a “sell (d+)” rating in a research report on Monday, May 11th. Two analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $168.40.

Insider Activity

In other ICU Medical news, Director David C. Greenberg sold 2,424 shares of the stock in a transaction dated Tuesday, May 12th. The stock was sold at an average price of $122.91, for a total value of $297,933.84. Following the completion of the transaction, the director directly owned 7,960 shares in the company, valued at approximately $978,363.60. This trade represents a 23.34% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, VP Virginia Ruth Sanzone sold 2,447 shares of the stock in a transaction dated Thursday, May 14th. The shares were sold at an average price of $124.08, for a total value of $303,623.76. Following the completion of the transaction, the vice president owned 19,460 shares of the company’s stock, valued at $2,414,596.80. This represents a 11.17% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 2.10% of the stock is currently owned by company insiders.

About ICU Medical

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.